Clinical and biological implications of driver mutations in myelodysplastic syndromesElli Papaemmanuil, Peter J. Campbell, Moritz Gerstung et al.|Blood|2013Cited by 1.8k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Sam Agresta et al.|Blood|2017Cited by 1.5k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring SideroblastsElli Papaemmanuil, Peter J. Campbell, Mario Cazzola et al.|New England Journal of Medicine|2011Cited by 1.2k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Michael Heuser et al.|Blood|2018Cited by 1k
MOLECULAR BIOLOGY OF THE CELLA. Victor Hoffbrand, Keith Gomez, Paresh Vyas et al.|Unknown|2018Cited by 262